VERU
VERU INC.
NASDAQ · Healthcare · Biotechnology · US
$2.31
+0.43%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.34
From 52W high−47.86%
Volume88103.00
Market cap$39.39M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.34
From 52W high
−47.86%
Volume
88103.00
Market cap
$39.39M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
45.6
MomentumView details →
1D Return
+0.43%
YTD Return
+9.35%
SummaryUpdated Jun 1, 2026
Veru Inc. (NASDAQ:VERU) is a Miami-based biopharmaceutical company that has undergone significant transformation since its founding in 1971. Originally established as The Female Health Company focused on women's health products, the company rebranded to Veru Inc. in 2017 to reflect its evolution into an oncology-focused drug development enterprise. Today, Veru operates as a clinical-stage biopharmaceutical company developing innovative treatments for cancer and other serious medical conditions, while maintaining a small commercial business in sexual health products.
Similar companies
Latest newsMore news →
Veru reported fiscal 2026 third quarter financial results and announced that its Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients.70d agoVeru announced that the U.S. Patent and Trademark Office issued a notice of allowance for a key methods-of-use patent covering enobosarm in combination with semaglutide for quality weight loss, with patent protection until at least October 2044.76d agoVeru Inc. announced full enrollment in its Phase 2b PLATEAU clinical trial evaluating enobosarm and semaglutide combination for weight loss.84d ago